A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 938 participants.

Also called NCT04657003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 938 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04657003
Other papers using this trial's data
  • Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet (London, England), 2023-08-19 DOI, PubMed 37385275

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, India, Japan, Puerto Rico, Russia, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04657003. Randomized; double masking; primary purpose treatment. Start 2021-03-29 (actual); primary completion 2023-03-16 (actual). Results posted on 2024-04-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Acronym
SURMOUNT-2
Condition
Overweight
Condition
Obesity
Intervention (Drug)
Tirzepatide
Intervention (Other)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04657003
Content hash
6a05a442120aa743c37d774c2b9408673ea2f225c965364400ef1241d92209de